Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials

Fig. 2

Efficacy of BA on total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), non high-density lipoprotein cholesterol (non HDL-C), Apolipoprotein B (Apo-B) and high sensitivity high reactive protein (hs-CRP). *Median observation period 52 weeks (interquartile range, IQR, 45–79.5) for TC, LDL-C, non HDL-C and hs-CRP); median observation period 52 weeks (IQR 38–52) for ApoB

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840